Hans T. Schambye net worth and biography

Hans Schambye Biography and Net Worth

CEO of Damora Therapeutics, Inc. Common Stock

Hans Schambye is a seasoned biotech entrepreneur with extensive experience in drug discovery and development. Previously, Hans served as the Chief Executive Officer of ReceptIcon from 2006 to 2009 and as the CEO of Gastrotech Pharma A/S from 2004 to 2006. Before joining Gastrotech, he was Director of Biology and Pharmacology and Head of Portfolio Management at Maxygen, a US biotech company. Hans has co-founded several biotech companies, including ProFound Pharma A/S, a Danish biotech company, which was acquired by Maxygen in 2000. Prior to this he had a successful research career at Stanford University and Copenhagen University within the field of receptor biology. Hans holds an MD from Odense University and a PhD in Medical Sciences from Copenhagen University.

What is Hans T. Schambye's net worth?: The estimated net worth of Hans T. Schambye is at least $120.89 thousand as of January 2nd, 2026. Dr. Schambye owns 4,682 shares of Damora Therapeutics, Inc. Common Stock stock worth more than $120,889 as of April 10th. This net worth approximation does not reflect any other investments that Dr. Schambye may own. Learn More about Hans T. Schambye's net worth.
How do I contact Hans T. Schambye?: The corporate mailing address for Dr. Schambye and other Damora Therapeutics, Inc. Common Stock executives is GALECTO BIOTECH AB OLE MAALOES VEJ3, COPENHAGEN G7, DK-2200. Damora Therapeutics, Inc. Common Stock can also be reached via phone at 45-7070-5210 and via email at [email protected]. Learn More on Hans T. Schambye's contact information.
Has Hans T. Schambye been buying or selling shares of Damora Therapeutics, Inc. Common Stock?: Hans T. Schambye has not been actively trading shares of Damora Therapeutics, Inc. Common Stock in the last ninety days. Most recently, Hans T. Schambye sold 700 shares of the business's stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $21.38, for a transaction totalling $14,966.00. Following the completion of the sale, the chief executive officer now directly owns 4,682 shares of the company's stock, valued at $100,101.16. Learn More on Hans T. Schambye's trading history.
Who are Damora Therapeutics, Inc. Common Stock's active insiders?: Damora Therapeutics, Inc. Common Stock's insider roster includes Jonathan Freve (CFO), Bertil Lindmark (Insider), Hans Schambye (CEO), and Garrett Winslow (General Counsel). Learn More on Damora Therapeutics, Inc. Common Stock's active insiders.
Are insiders buying or selling shares of Damora Therapeutics, Inc. Common Stock?: In the last year, insiders at the sold shares 4 times. They sold a total of 1,717 shares worth more than $20,838.98. The most recent insider tranaction occured on January, 2nd when CEO Hans T Schambye sold 700 shares worth more than $14,966.00. Insiders at Damora Therapeutics, Inc. Common Stock own 10.5% of the company. Learn More about insider trades at Damora Therapeutics, Inc. Common Stock.
Information on this page was last updated on 1/2/2026.

Hans T. Schambye Insider Trading History at Damora Therapeutics, Inc. Common Stock

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/2/2026	Sell	700	$21.38	$14,966.00	4,682
7/3/2025	Sell	735	$3.38	$2,484.30	4,022
1/3/2025	Sell	1,341	$5.60	$7,509.60	3,397
3/22/2022	Buy	200	$53.75	$10,750.00
11/9/2021	Buy	180	$87.50	$15,750.00
6/24/2021	Buy	120	$127.75	$15,330.00	1,717

Hans T. Schambye Buying and Selling Activity at Damora Therapeutics, Inc. Common Stock

Damora Therapeutics, Inc. Common Stock Company Overview

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Today's Range

Now: $25.82

$25.55

$27.88

50 Day Range

MA: $26.81

$18.14

$32.30

2 Week Range

Now: $25.82

$2.14

$38.33

Volume

287,217 shs

Average Volume

276,563 shs

Market Capitalization

$1.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59